Camurus Stock

Camurus EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Camurus (CAMX.ST) as of Aug 4, 2026 is 884.17 M SEK. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 483.94 M SEK — a change of 82.70% (higher).

EBITDA

884.17 MSEK

YoY

82.70%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Camurus is 2026 884.17 M SEK. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Camurus was 2025 483.94 M SEK. It decreases by 82.70% higher compared to the previous year.
Access this data via the Eulerpool API

Camurus Stock analysis

What does Camurus do? Camurus AB is a Swedish biopharmaceutical company that specializes in the development of innovative medications for the treatment of serious diseases. The company was founded in 1991 by an interdisciplinary team of chemists, biologists, and drug developers and is headquartered in Lund, Sweden. Camurus AB specializes in the development of medications based on long-acting drug release technology. This technology allows medications to be administered in a very precise manner and over a longer period of time. This enables the benefits of a constant drug concentration in the blood to be utilized without requiring multiple doses per day. The core business of Camurus AB includes the development of medications for the treatment of pain, cancer, and addiction. The company works closely with clients, partners, and academic institutions to bring innovative medications to market that can have a significant impact on patients' lives. One of Camurus AB's key areas is pain therapy. The company has developed a novel technology that allows pain medications to be administered in the form of sprays and patches. This technology is based on the release of buprenorphine, a potent painkiller that previously could only be administered as repeated single doses or in the form of an implant due to its short half-life. The extended release allows for a sustained high concentration of the drug in the blood, without the need for the patient to take multiple single doses. Camurus AB is also active in oncology and has developed medications for the treatment of breast and prostate cancer that also utilize long-acting drug release. These medications help patients better tolerate the side effects of chemotherapy and improve their quality of life. Another important area for Camurus AB is addiction therapy. The company has developed a medication based on buprenorphine for the treatment of opioid dependence. This medication activates the body's own opioid receptors and reduces the cravings for further drugs. In recent years, Camurus AB has introduced several important products to the market and holds a wide portfolio of patents and protective rights. The company is committed to improving patient care and making global healthcare a better and more effective system. In conclusion, Camurus AB is an innovative biopharmaceutical company specializing in the development of medications for the treatment of pain, cancer, and addiction. The company is dedicated to improving global healthcare and works closely with clients, partners, and academic institutions to develop innovative, effective, and patient-oriented solutions. Camurus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Camurus stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Camurus is 884.17 M SEK in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Camurus changed from 483.94 M SEK to 884.17 M SEK, representing a 82.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Camurus since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Camurus historically and in real time.

Access this data via the Eulerpool API

Income Statement — Camurus

All Key Metrics — Camurus